Return to Listing

12 result(s) for Gastrointestinal Cancers

PI Name Protocol # Title
Vassiliki Tsikitis IRB00003082 Oregon Colorectal Cancer Registry
Brett Sheppard IRB00003609 Oregon Pancreas Tumor Registry
Kevin Billingsley IRB00005222 Oregon Liver Tumor Registry
Charles Thomas IRB00009013 A Study to Determine the Immune Profile of Rectal Adenocarcinoma and its Correlation with the Efficacy of Neoadjuvant Chemoradiotherapy
Gina Vaccaro IRB00009414 A Phase III Study of FOLFIRINOX with or without Hyperacute-Pancreas (Algenpantucel-L) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Rodney Pommier IRB00009420 Oregon Index of Endocrine Neoplasias (ORION)
Erin Gilbert IRB00009694 The Use of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in the Management of Pancreatic Cancer
Paul Spellman IRB00010163 Reconstructing the Tumor Genome in Peripheral Blood
Charles Lopez IRB00010540 A Phase III, Multicenter, Open-Label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma
Charles Lopez IRB00010768 A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor, Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy
Daniel Herzig IRB00011161 A Phase II Multicenter Randomized Trial Evaluating 3-Year Disease-Free Survival in Patients with Locally Advanced Rectal Cancer Treated with Chemoradiation Plus Induction or Consolidation Chemotherapy, and Total Mesorectal Excision or Non-Operative Management
Gina Vaccaro IRB00011746 I4T-MC-JVDE: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080